Fox Chase Cancer Center study: some prostate cancers may be more sensitive to radiation treatment

October 23, 2000

PHILADELPHIA (October 24, 2000) -- Radiation treatment for prostate cancer is more effective in tumor cells in which the DNA is structurally compact. That is the result of a new study that was presented at the American Society for Therapeutic Radiology and Oncology Annual Meeting in Boston, Mass. on Tuesday, October 24, at 11:45 a.m.

In the study completed at Fox Chase Cancer Center, human prostate cancer cells were irradiated in tissue culture and the survival measured by clonogenic assays. The degree of compaction of the chromatin was chemically altered by okadaic acid (OA), fostriecin (FC) and tricostatin A (TSA). Both electron microscopy and flourescence confocal microscopy were used to measure the compaction of the chromatin in interphase cells.

Microscopy examination of irradiated drug-treated cells showed a significant increase in molecular compaction. Radiation survival studies of the tumor cells after adding FC and TSA show that the cells were significantly radiosensitized and thus were more susceptible to irradiation.

"These data suggest that there is a direct correlation between irradiation and the compaction status of chromatin in tumor cells," explained Jim Wurzer, M.D., the author of the study. "In addition, information from these data may allow physicians to examine a biopsy specimen and predict the radiosensitivity of cells in individual cancers. In the future, we may be able to use chemical agents to manipulate the cells in tumors to make them more sensitive to treatment."

Fox Chase Cancer Center, one of the nation's first comprehensive cancer centers designated by the National Cancer Institute in 1974, conducts basic and clinical research; programs of prevention, detection and treatment of cancer; and community outreach. For more information about Fox Chase activities, visit the Center's web site at www.fccc.edu.
-end-
Abstract # 120 DNA Compaction and Radiation-induced Cell Killing in Human Prostate Cancer Cells to be presented Oct. 24, 2000, 11:45 a.m. (Dr. Jim Wurzer was a research fellow in the Department of Radiation Oncology at Fox Chase Cancer Center and now practices at Atlantic City Medical Center in Pomona, New Jersey.)

Fox Chase Cancer Center

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.